Characteristics | Values |
Age (years) | 61.5 (49.5:71) |
Female sex | 62 (73.8) |
Ethnicity | |
Caucasian | 81 (96.4) |
African | 1 (1.2) |
Maghrebian | 2 (2.4) |
BMI (kg/m2) | 26.1 (22.7:30.1) |
Number of treatments per day | 3 (1:5) |
Number of tablets per day | 3 (1:5) |
Comorbidities (Charlson Score) | 3 (2:5) |
Immunopositivity (CCP and/or RF) | 63 (75) |
Disease duration (months) | 130.5 (41:202.5) |
Duration of MTX treatment (months) | 94.5 (27:164) |
MTX dose (mg/week) | 15 (11.2:20) |
MTX administration mode | |
PO | 26 (30.9) |
SC | 58 (69.1) |
Biologic therapy at inclusion | 52 (61.9) |
Usual follow-up | |
Outpatient consultation | 51 (60.7) |
Day hospitalisation | 33 (39.3) |
RA activity at inclusion | |
Remission | 47 (55.9) |
Low | 10 (11.9) |
Moderate | 22 (26.2) |
High | 5 (5.9) |
DAS28-CRP at inclusion | 2.38 (1.75:3.72) |
CRP (mg/L) | 4 (1:8.4) |
Albumin (g/L)* | 41.1 (39.3:44) |
MCV (fL) | 94 (91:96) |
Qualitative variables are expressed as frequency (%), and quantitative variables are expressed as median (Q1:Q3). RA activity was determined based on the DAS-CRP value at inclusion.
*10 missing data.
BMI, body mass index; CCP, Cyclic Citrullinated Peptides; CRP, C reactive protein; DAS28, Disease Activity Score-28; MCV, mean corpuscular volume; MTX, methotrexate; PO, oral; RA, rheumatoid arthritis; RF, Rheumatoid Factor; SC, subcutaneous.